JB Chemicals & Pharmaceuticals (506943) investor relations material

Executive summary

• Q4 FY26 marked the first quarter post-acquisition by Torrent Pharma, with operational reset impacting performance and normalization expected from Q1 FY27 onward.

• Integration steps included distribution optimization, discontinuation of low-margin trade generics, and alignment of sales practices.

• Audited standalone and consolidated financial results for the year ended March 31, 2026, were approved by the Board and received unmodified opinions from auditors.

• The company is in the process of amalgamating with Torrent Pharmaceuticals Limited, with all shareholder and regulatory approvals in progress; legal completion expected within 1-2 months.

Financial highlights

• Q4 FY26 revenue was INR 904 crores, a 5% year-over-year decline.

• Adjusted EBITDA was flat at INR 241 crores after excluding INR 40 crores of one-off charges.

• Gross margin improved to 70% from 66% year-over-year; adjusted EBITDA margin rose to 27% from 25%.

• Consolidated revenue from operations for FY26 was ₹4,14,779 lakhs, up from ₹3,91,799 lakhs year-over-year.

• Reported net profit after tax was INR 101 crores; adjusted for one-offs, net profit was INR 150 crores.

• Consolidated net profit after tax for FY26 was ₹70,947 lakhs, compared to ₹65,958 lakhs in FY25.

• Final dividend of INR 9.3 per share recommended for FY26.

Outlook and guidance

• India business expected to return to double-digit growth in a couple of quarters; international business to resume single-digit growth from Q2 FY27.

• Gross margin improvement expected to sustain, with further clarity after Q1 FY27.

• CDMO business anticipated to regain positive momentum over the next 12 months, contingent on improved execution.

• The amalgamation with Torrent Pharmaceuticals is expected to proceed following NCLT approval, with an appointed date of January 21, 2026.